Grundlaget for denne analyse var, at mindst 100 patienter (> 5% af den undersøgte population) blev behandlet samtidigt med disse lægemidler i mindst 90% af forsøgsperioden.
The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period.